Capricor Therapeutics, Inc. (CAPR)

Market Cap	1.54B
Revenue (ttm)	11.13M
Net Income (ttm)	-81.99M
Shares Out	51.72M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	908,378
Open	29.53
Previous Close	29.68
Day's Range	29.20 - 29.98
52-Week Range	4.30 - 40.37
Beta	0.61
Analysts	Strong Buy
Price Target	41.38 (+39.37%)
Earnings Date	Nov 10, 2025

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 160
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR
• Website: https://www.capricor.com

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price target is $41.38, which is an increase of 39.37% from the latest price.

Price Target

$41.38

(39.37% upside)

Analyst Consensus: Strong Buy